Jim: I think Evercore/ISI is a little arrogant for suggesting that the various companies pursing FXR agonists for NASH are out to lunch. Time will tell.
p.s. Congratulations on your MDGL gains to date!
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”